2. Advances in pharmacotherapy for COPD

Masakazu Ichinose

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world (1). In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease (1). Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world (1-3). Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published (3, 4). These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD (3, 4).

Original languageEnglish
Pages (from-to)81-84
Number of pages4
JournalInternal Medicine
Issue number2
Publication statusPublished - 2007 Jan 15


  • Bronchodilators
  • Inhaled steroid
  • Nitrotyrosine

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of '2. Advances in pharmacotherapy for COPD'. Together they form a unique fingerprint.

Cite this